{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:43:39Z","timestamp":1790052219441,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.<\/jats:p>","DOI":"10.1007\/s12032-021-01513-x","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T04:03:56Z","timestamp":1626235436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Computational study on novel natural inhibitors targeting BCL2"],"prefix":"10.1007","volume":"38","author":[{"given":"Xiaye","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaoQun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaojing","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-9224","authenticated-orcid":false,"given":"Zijian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghe","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"issue":"11","key":"1513_CR1","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"The Non-Hodgkin's Lymphoma Classification Project","year":"1997","unstructured":"The Non-Hodgkin\u2019s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma. Blood. 1997;89(11):3909\u201318.","journal-title":"Blood"},{"issue":"12","key":"1513_CR2","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12): 2040\u20132045.","journal-title":"Blood"},{"issue":"14","key":"1513_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"issue":"5","key":"1513_CR4","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.21873\/anticanres.11613","volume":"37","author":"M Yamamoto","year":"2017","unstructured":"Yamamoto M, Watanabe K, Fukuda T, et al. Prediction of prognosis for patients with diffuse large B-cell lymphoma refractory to or in first relapse after initial R-CHOP therapy: a single-institution study. Anticancer Res. 2017;37(5):2655\u201362.","journal-title":"Anticancer Res"},{"issue":"15","key":"1513_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396\u2013407.","journal-title":"N Engl J Med"},{"issue":"6","key":"1513_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/bib\/bbq022","volume":"11","author":"PS Cooper","year":"2010","unstructured":"Cooper PS, Lipshultz D, Matten WT, et al. Education resources of the National Center for Biotechnology Information. Brief Bioinform. 2010;11(6):563\u20139.","journal-title":"Brief Bioinform"},{"issue":"4","key":"1513_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.leu.2402090","volume":"15","author":"PP Ruvolo","year":"2001","unstructured":"Ruvolo PP, Deng X, May WS. Phosphorylation of BCL2 and regulation of apoptosis. Leukemia. 2001;15(4):515\u201322.","journal-title":"Leukemia"},{"issue":"6","key":"1513_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0092-8674(00)00187-2","volume":"103","author":"DC Huang","year":"2000","unstructured":"Huang DC, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell. 2000;103(6):839\u201342.","journal-title":"Cell"},{"issue":"51","key":"1513_CR9","doi-asserted-by":"publisher","first-page":"20327","DOI":"10.1073\/pnas.0808036105","volume":"105","author":"JE Chipuk","year":"2008","unstructured":"Chipuk JE, Fisher JC, Dillon CP, et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA. 2008;105(51):20327\u201332.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"1513_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1046\/j.1365-2443.1998.00223.x","volume":"3","author":"Y Tsujimoto","year":"1998","unstructured":"Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3(11):697\u2013707.","journal-title":"Genes Cells"},{"issue":"1","key":"1513_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cdd.2017.179","volume":"25","author":"H Kalkavan","year":"2018","unstructured":"Kalkavan H, Green DR. MOMP, cell suicide as a BCL-2 family business. Cell Death Differ. 2018;25(1):46\u201355.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1513_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25(1):65\u201380.","journal-title":"Cell Death Differ"},{"issue":"3","key":"1513_CR13","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.bbrc.2016.11.088","volume":"482","author":"H Vakifahmetoglu-Norberg","year":"2017","unstructured":"Vakifahmetoglu-Norberg H, Ouchida AT, Norberg E. The role of mitochondria in metabolism and cell death. Biochem Biophys Res Commun. 2017;482(3):426\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1513_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","volume":"21","author":"FJ Bock","year":"2020","unstructured":"Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21(2):85\u2013100.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4 Suppl 5","key":"1513_CR15","first-page":"9","volume":"34","author":"JC Reed","year":"1997","unstructured":"Reed JC. Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Semin Hematol. 1997;34(4 Suppl 5):9\u201319.","journal-title":"Semin Hematol"},{"key":"1513_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","volume":"137","author":"S Maji","year":"2018","unstructured":"Maji S, Panda S, Samal SK, et al. Bcl-2 Antiapoptotic family proteins and chemoresistance in cancer. Adv Cancer Res. 2018;137:37\u201375.","journal-title":"Adv Cancer Res"},{"issue":"5","key":"1513_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2141.2011.08669.x","volume":"153","author":"EA Brem","year":"2011","unstructured":"Brem EA, Thudium K, Khubchandani S, et al. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol. 2011;153(5):599\u2013611.","journal-title":"Br J Haematol"},{"issue":"12","key":"1513_CR18","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3109\/10428194.2014.907891","volume":"55","author":"A Goy","year":"2014","unstructured":"Goy A, Hernandez-Ilzaliturri FJ, Kahl B. A phase I\/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk Lymphoma. 2014;55(12):2761\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"1513_CR19","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-07-1919","volume":"68","author":"M Konopleva","year":"2008","unstructured":"Konopleva M, Watt J, Contractor R, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008;68(9):3413\u201320.","journal-title":"Cancer Res"},{"issue":"18","key":"1513_CR20","doi-asserted-by":"publisher","first-page":"29558","DOI":"10.18632\/oncotarget.16365","volume":"8","author":"CT Ishida","year":"2017","unstructured":"Ishida CT, Bianchetti E, Shu C, et al. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma. Oncotarget. 2017;8(18):29558\u201373.","journal-title":"Oncotarget"},{"issue":"6","key":"1513_CR21","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1021\/ci6004299","volume":"47","author":"SN Rao","year":"2007","unstructured":"Rao SN, Head MS, Kulkarni A, et al. Validation studies of the site-directed docking program LibDock. J Chem Inf Model. 2007;47(6):2159\u201371.","journal-title":"J Chem Inf Model"},{"issue":"10","key":"1513_CR22","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks CL 3rd, Mackerell AD Jr, et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545\u2013614.","journal-title":"J Comput Chem"},{"issue":"1","key":"1513_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10822-014-9807-2","volume":"29","author":"S Sarvagalla","year":"2015","unstructured":"Sarvagalla S, Singh VK, Ke YY, et al. Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity. J Comput Aided Mol Des. 2015;29(1):89\u2013100.","journal-title":"J Comput Aided Mol Des"},{"issue":"9","key":"1513_CR24","doi-asserted-by":"publisher","first-page":"e74761","DOI":"10.1371\/journal.pone.0074761","volume":"8","author":"K Kalani","year":"2013","unstructured":"Kalani K, Agarwal J, Alam S, et al. In silico and in vivo anti-malarial studies of 18\u03b2 glycyrrhetinic acid from Glycyrrhiza glabra. PLoS One. 2013;8(9):e74761.","journal-title":"PLoS One"},{"issue":"2","key":"1513_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"1513_CR26","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/ijms20040860","volume":"20","author":"J Ramos","year":"2019","unstructured":"Ramos J, Muthukumaran J, Freire F, et al. Shedding light on the interaction of human anti-apoptotic Bcl-2 protein with ligands through biophysical and in silico studies. Int J Mol Sci. 2019;20(4):860.","journal-title":"Int J Mol Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-021-01513-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-021-01513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:20:30Z","timestamp":1627345230000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-021-01513-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s12032-021-01513-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-185749\/v1","asserted-by":"object"}]},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"25 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"There is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"94"}}